Last reviewed · How we verify
Medium dose prednisolone
Medium dose prednisolone, marketed by the Post Graduate Institute of Medical Education and Research, Chandigarh, holds a position in the corticosteroid segment with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and broad therapeutic use, which supports its continued market presence. The primary risk is the potential increase in competition following the 2028 patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Medium dose prednisolone |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PHASE1, PHASE2)
- Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients (PHASE1)
- Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
- 3TR Asthma Biologics Cohort (ABC) Study
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Stratified Therapy on Pediatric AAGN (PHASE4)
- Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids (PHASE1)
- Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: